Lantern Pharma Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINESCHEDULE 13G/ALantern Pharma Inc.LTRN5d

   Lantern Pharma Inc. 4.99% stake reported

   • Empery Asset Management, LP holds 755,891 shares
   • Ryan M. Lane holds 755,891 shares
   • 4.99% of outstanding shares

   Empery Asset Management, LP, filed by

2. ROUTINEPRE 14ALantern Pharma Inc.LTRNOct 8

   Lantern Pharma Inc. announces 2026 annual meeting

   • Annual meeting on December 1, 2026
   • 6 directors to be elected
   • Increase authorized common stock to 50 million shares
3. ROUTINE8-KLantern Pharma Inc.LTRNOct 1

   Current report

4. ROUTINE8-KLantern Pharma Inc.LTRNSep 30

   Current report

5. ROUTINE424B5Lantern Pharma Inc.LTRNSep 30

   Securities offering

6. ROUTINE8-KLantern Pharma Inc.LTRNSep 24

   Current report

7. ROUTINE8-KLantern Pharma Inc.LTRNSep 23

   Current report

8. ROUTINE8-KLantern Pharma Inc.LTRNAug 14

   Current report

9. NOTABLE10-QLantern Pharma Inc.LTRNAug 14

   Quarterly report

10. ROUTINESCHEDULE 13GLantern Pharma Inc.LTRNAug 4

    Ownership stake disclosure by Empery Asset Management, LP

    Empery Asset Management, LP, filed by

11. ROUTINE8-KLantern Pharma Inc.LTRNAug 3

    Current report

12. ROUTINESCHEDULE 13G/ALantern Pharma Inc.LTRNJul 23

    Ownership stake disclosure by Thomas A Satterfield Jr (amended)

    Thomas A Satterfield Jr, filed by

13. ROUTINEEFFECTLantern Pharma Inc.LTRNJun 22

    Registration declared effective

14. NOTABLES-1Lantern Pharma Inc.LTRNJun 12

    Securities offering

15. ROUTINEDLantern Pharma Inc.LTRNMay 21

    Private placement notice

16. NOTABLESCHEDULE 13D/ALantern Pharma Inc.LTRNMay 15

    Ownership stake disclosure by Bios Equity Partners, LP (amended)

    Bios Equity Partners, LP, filed by

17. ROUTINE8-KLantern Pharma Inc.LTRNMay 15

    Current report

18. NOTABLE10-QLantern Pharma Inc.LTRNMay 15

    Quarterly report

19. ROUTINE8-KLantern Pharma Inc.LTRNMay 14

    Current report

20. ROUTINE4Lantern Pharma Inc.LTRNMay 14

    2 insider filings

    D Jeffrey Keyser, insider filing for LTRN

    Show all 2

    • 4Insider filing for LTRNMay 14
    • 4Insider filing for LTRNMay 14

    D Jeffrey Keyser, reporting

21. ROUTINE424B5Lantern Pharma Inc.LTRNMay 14

    Securities offering

22. ROUTINE10-K/ALantern Pharma Inc.LTRNApr 30

    Annual report (amended)

23. NOTABLESCHEDULE 13D/ALantern Pharma Inc.LTRNApr 16

    Ownership stake disclosure by Bios Equity Partners, LP (amended)

    Bios Equity Partners, LP, filed by

24. ROUTINE8-KLantern Pharma Inc.LTRNApr 10

    Current report

25. ROUTINESCHEDULE 13GLantern Pharma Inc.LTRNApr 3

    Ownership stake disclosure by Thomas A Satterfield Jr

    Thomas A Satterfield Jr, filed by

26. ROUTINE424B5Lantern Pharma Inc.LTRNMar 30

    Securities offering

27. NOTABLE10-KLantern Pharma Inc.LTRNMar 30

    Annual report

28. ROUTINE8-KLantern Pharma Inc.LTRNMar 30

    Current report

29. NOTABLESCHEDULE 13D/ALantern Pharma Inc.LTRNFeb 23

    Ownership stake disclosure by Bios Equity Partners, LP (amended)

    Bios Equity Partners, LP, filed by

30. ROUTINE8-KLantern Pharma Inc.LTRNJan 23

    Current report

31. ROUTINE4Lantern Pharma Inc.LTRNJan 13

    5 insider filings

    David S. Silberstein, insider filing for LTRN

    Show all 5

    • 4Insider filing for LTRNJan 13
    • 4Insider filing for LTRNJan 13
    • 4Insider filing for LTRNJan 13
    • 4Insider filing for LTRNJan 13
    • 4Insider filing for LTRNJan 13

    David S. Silberstein, reporting

32. ROUTINE4Lantern Pharma Inc.LTRNDec 22, 2025

    2 insider filings

    David R. Margrave, insider filing for LTRN

    Show all 2

    • 4Insider filing for LTRNDec 22, 2025
    • 4Insider filing for LTRNDec 22, 2025

    David R. Margrave, reporting

33. ROUTINE8-KLantern Pharma Inc.LTRNNov 13, 2025

    Current report

34. NOTABLE10-QLantern Pharma Inc.LTRNNov 12, 2025

    Quarterly report

Older filings on EDGAR